Development of CNS model for neurodegenerative drug discovery using 3D printed human iPSC-derived cells

There is a lack of effective medicines for the treatment of neurodegenerative diseases. This challenge is also coupled with a lack of validated preclinical models, which is limiting drug development and successful progression to clinical trial. Over the past decade, considerable effort has been devoted to improving in vitro preclinical models of the central nervous system (CNS) to more accurately replicate brain structure and function.

One promising direction includes the development of complex 3D models such as bio-printed models which more closely mimic the intricate cell-cell and cell-extracellular matrix interactions observed in vivo. Increasing evidence suggests that 3D models more effectively reproduce the pathological processes of neurodegenerative diseases when compared to traditional 2D systems, making them potentially more predictive and valuable for translational drug discovery.

Poster





View the poster here







new board appointments
News
15 September 2026
Medicines Discovery Catapult appoints global life science and commercialisation leaders to its Board of Directors

New appointments support MDC’s mission to turn drug discovery into commercial breakthroughs.


News
10 September 2026
Inspiring the next generation: Medicines Discovery Catapult scientist contributes to children’s science book 

Dr Emma Jones, a Lead Scientist in in vitro Neurobiology at Medicines Discovery Catapult (MDC), has contributed to a new children’s book celebrating the diversity of careers in science.


News
03 September 2026
Medicines Discovery Catapult invests in UK biotech pioneers developing novel treatments for chronic diseases

Investment and expert support will help accelerate the development of new treatments for a range of autoimmune, inflammatory, and age-related diseases.





Medicines Discovery Catapult